BR-AG
18.5.2022 10:05:12 CEST | Business Wire | Press release
As regulatory reporting requirements become more complex and regulators become more demanding on the data quality, financial institutions must deal with time-consuming regulatory reporting processes and manage the associated risks. Tapping into this challenge, PwC Belgium, with the support of technology-collaborator BR-AG, developed Regulatory Reporting Insights , powered by BR-AG’s ATOME Matter and ATOME Particles solutions.
“I am excited about the opportunities this improved collaboration with our trusted technology partner BR-AG will bring. This allows financial institutions not only immediate access to an increased level of trust in their regulatory reporting but also to unlock the insights their regulatory reporting contains that was previously only accessible to supervisors.”
Jeroen Bockaert, Partner and Product & Services Leader at PwC Belgium
“It is truly inspiring that our collaboration with PwC has coined into developing this cutting-edge, data-driven tool. As technology experts, we focus on scalability and reusability of data architecture for different purposes and, above all, trust in the solutions we provide. This is indeed a step forward towards a new reporting culture for financial institutions, who now gain such a level of data insight and trust that compliance and risk mitigation become seamless. This is essential for their sustainable growth.”
Michał Piechocki, CEO and co-founder of Business Reporting Advisory Group (BR-AG)
Technology at the heart of the regulatory reporting value chain
Trust in data is the core component of any endeavor within the regulatory reporting sphere and goes beyond compliance. With extremely demanding regulatory reporting requirements at the heart, companies are turning to trusted advisors to streamline their reporting processes and incorporate the most effective and reliable solutions. Bringing together PwC years’ long experience in providing services to financial institutions and BR-AG’s know-how in applying technology to regulatory reporting processes, the end result is a platform to facilitate trust across the reporting value chain and use data insights to their maximum potential.
Different needs, one ecosystem
Understanding the variety of needs across department stakeholders, Regulatory Reporting Insights caters to the data demands of multiple teams managing finance, risk, and regulatory reporting. Powered by BR-AG’s ATOME Matter and ATOME Particles, the platform translates complex reports into visual insights of key regulatory reporting information and adds a layer of comfort to your data quality assurance.
About BR-AG:
Business Reporting- Advisory Group (BR-AG) is a Polish company providing RegTech solutions for financial institutions in Europe and services in utilizing data exchange standards such as XBRL, ISO 20022 and SDMX. By fusing our experience in the regulatory data and technology space, BR-AG developed regulatory data platforms: ATOME Matter and ATOME Particles to foster interoperability, agility, and collaboration in regulatory compliance.
About PwC Belgium:
At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 155 countries with more than 284,000 people who are committed to delivering quality in assurance, advisory and tax services.
Find out more and tell us what matters to you by visiting us at www.pwc.be .
PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220515005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom